Compare XRAY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | IMNM |
|---|---|---|
| Founded | 1899 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2009 | 2020 |
| Metric | XRAY | IMNM |
|---|---|---|
| Price | $10.47 | $18.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $14.58 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 5.8M | 1.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | 33.04 | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $7.96 |
| 52 Week High | $17.09 | $27.65 |
| Indicator | XRAY | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 34.39 |
| Support Level | $9.63 | $16.81 |
| Resistance Level | $10.65 | $19.16 |
| Average True Range (ATR) | 0.47 | 1.23 |
| MACD | 0.10 | -0.32 |
| Stochastic Oscillator | 83.06 | 8.72 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.